Does Cyp3a Inducers Interact with Selpercatinib?
Cyp3a Inducers and Selpercatinib have a moderate drug interaction according to U.S. FDA drug labeling data. Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration. The mechanism involves cyp3a induction decreases selpercatinib plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Selpercatinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inducers and Selpercatinib occurs because cyp3a induction decreases selpercatinib plasma concentrations. Clinically, this means concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. avoid coadministration. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Selpercatinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider